OraVerse® Efficacy
Like any new advancement, OraVerse has to meet your standards for efficacy across the board. We've dedicated years to studying and understanding the effectiveness of OraVerse. Phentolamine mesylate, the active ingredient in OraVerse, has been used in medical applications since 1952. As you'll see below, the clinical trials for OraVerse have yielded positive results.
Get your patients' feeling back faster.
OraVerse is the first and only local anesthesia reversal agent that accelerates the return to normal sensation and function after routine dental procedures where local anesthetic containing a vasoconstrictor was used. In clinical trials, the patients were able to regain normal sensation twice as fast.*
Median Time to Normal Lip Sensation
(Adult and Adolescent Clinical Trials)
These trials showed that on average, OraVerse patients not only return to normal sensation faster, but they can speak, smile and drink sooner and drooling is minimized.
Median Time to Recovery of Normal Function
OraVerse is indicated for reversal of soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than 6 years of age or weighing less than 15 kg (33 lbs).
Important Safety Information
In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents. See full prescribing information for details.
*Hersh EV, Moore PA, Papas AS, and colleagues. Reversal of soft-tissue anesthesia with phentolamine mesylate in adolescents and adults. JADA 2008;139(8):1080-1093. Copyright ©2008 American Dental Association. All rights reserved. Excerpted by permission.
